Prostacyclin analogue formulations

US11369617B2 · kind B2 · utility

Assignee

• CAMURUS AB · SE

Inventors

• Fredrik Tiberg · Lund, SE
• Justas Barauskas · Lund, SE
• Catalin Nistor · Lund, SE
• Markus Johnsson · Lund, SE

Key dates

• Filing date: Sep 15, 2017
• Grant date: Jun 28, 2022
• Expiry date: Dec 28, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an injectable pre-formulation comprising: a) at least one of a mono-, di-, or tri-acyl lipid and/or a tocopherol; b) optionally at least one phospholipid; c) at least one biocompatible, organic solvent; and d) at least one prostacyclin analogue or a salt thereof; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynard's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.